Ashanul Haque

Publications (13) View all

• Article: Analyses of Anticancer Drugs by Capillary Electrophoresis: A Review.

  Imran Ali, Ashanul Haque, Waseem A. Wani, Kishwar Saleem
  [show abstract] [hide abstract]
  ABSTRACT: Capillary electrophoresis is a highly sensitive, economic and energy saving electro-analytical technique of wide utility in pharmaceutical and allied fields. It finds diverse uses in the analysis of proteins, peptides, nucleic acids, nucleotides, carbohydrates, fatty acids, drugs, drug candidates and their metabolites in biological fluids and, therefore, acts as biomarker for monitoring the states of various chronic diseases. The versatility of capillary electrophoresis gives it a unique position over other chromatographic techniques. The present article describes the state-of-art of capillary electrophoresis for the development of anticancer drugs in the recent years. In addition, future perspectives of the analysis of cytotoxic drugs by electrophoresis have been have been discussed.
  Biomedical Chromatography 05/2013; · 1.97 Impact Factor
• Article: Glutamic Acid and its Derivatives: Candidates for Rational Design of Anticancer Drugs

  Imran Ali, Waseem A. Wani, Ashanul Haque, Kishwar Saleem
  [show abstract] [hide abstract]
  ABSTRACT: Throughout the history of human civilizations, cancer has been a major killer. Its treatment has been interesting but a quite challenging job to scientists. Glutamic acid and its derivative glutamine are known to play interesting roles in cancer genesis. It was realized that structurally variant glutamic acid derivatives may be designed and developed and, might be having antagonistic effects towards cancer. The present article describes the state-of-art of glutamic acid and its derivatives as anticancer agents. Attempts have been made to explore the effectivity of drug delivery systems based on glutamic acid for the delivery of anticancer drugs. Moreover, efforts have also been made to discuss the mechanism of action of glutamic acid derivatives as anticancer agents, clinical applications of glutamic acid derivatives and recent developments and future perspectives of glutamic acid drug development.
  Future medicinal chemistry 03/2013; 5(8):961-978. · 2.52 Impact Factor
• Article: Synthesis, DNA binding, hemolysis assays and anticancer studies of copper(II), nickel(II) and iron(III) complexes of a pyrazoline-based ligand.

  Kishwar Saleem, Waseem A Wani, Ashanul Haque, Mohamad Nadeem Lone, Ming-Fa Hsieh, Mohamad Aman Jairajpuri, Imran Ali
  [show abstract] [hide abstract]
  ABSTRACT: Background: Over the last few decades, metal-based drugs, particularly cisplatin and its analogs have been used for the treatment of various cancers. Currently, scientists are developing other metal complexes as anticancer agents to eliminate the toxicity associated with platinum drugs. Results: Claisen-Schmidt condensation was used to synthesize the pyrazoline-based ligand; (5-(4-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide), followed by the synthesis of its complexes with copper(II), nickel(II) and iron(III) metal ions. DNA binding and in silico studies indicated quite good binding with DNA; requirements for good anticancer drugs. Conclusion: DNA binding constants for ligand, copper, nickel and iron complexes were 1.42 × 10(4), 3.16 × 10(4), 5.82 × 10(5) and 6.72 × 10(5) M(-1), respectively, indicating strong binding with DNA. All the reported compounds were slightly hemolytic towards rabbit red blood corpuscles and exhibited moderate activities against MCF-7 cancer cell lines.
  Future medicinal chemistry 02/2013; 5(2):135-46. · 2.52 Impact Factor
• Article: New Generation Halo Column for Fast Analyses of Aspirin and Atorvastatin in Pharmaceutical Preparation.

  Imran Ali, Kishwar Saleem, Ashanul Haque, Waseem A. Wani, Vinay D. Gaitode
  [show abstract] [hide abstract]
  ABSTRACT: A super fast (within 4 min. only) HPLC method is described for the analyses of aspirin and atorvastatin simultaneously in single dosage formulation. The mobile phase used was water (pH 2.0, adjusted by o-phosphoric acid)-acetonitrile (50:50, v/v) at 1.0 mL/min flow rate with 210 nm detection. The column used was new generation Halo C18 (100 x 46 mm; shell particles; 2.7 µm). The capacity factors of aspirin and atrorvastatin were 1.20 and 2.01, while the separation and resolution factors were 1.68 and 5.63, respectively. The values of LOD and LOQ for aspirin were 0.10 and 0.50 μg/mL, while these values for atorvastatin were 0.50 and 2.5 μg/mL, respectively. The linearity was observed in the ranges of 0.1 to 5.0 mg/mL for both drugs. The reported method can be used for the quality control of aspirin and atrorvastatin in pharmaceutical preparations with good economy. Besides, this method can also be used for the analyses of aspirin and atorvastatin drugs in biological and environmental samples.
  J. Liq. Chromatogr. Relat. Technol. 01/2013; 36(3):261-73.
• Article: Platinum Compounds: A Hope for Future Cancer Chemotherapy.

  Imran Ali, Waseem A Wani, Kishwar Saleem, Ashanul Haque
  [show abstract] [hide abstract]
  ABSTRACT: The discovery of cis-platin and its second and third generation analogues created a hope in cancer chemotherapy. Cis-platin and its second generation analogue carboplatin have been used for the treatment of some cancers from a long time. The third generation analogues have superior anti-cancer profiles for curing a few cancers. Unfortunately, certain side effects such as renal impairment, neurotoxicity and ototoxicity etc. are associated with these drugs. But, combination therapy makes these analogues more effective with fewer side effects. In addition, the results of some ongoing clinical trials will make the safety profile clear in near future. The present article describes the current status of cis-platin and its analogues in cancer chemotherapy. In addition, special emphasis has been made on cis-platin discovery, development of second (carboplatin, oxaliplatin, nedaplatin) and third (lobaplatin, heptalatin) generation analogues, comparison of their chemotherapies, mechanism of action, therapeutic status, recent developments and chronology. Moreover, attempts have been made to describe the future perspectives of these drugs in the cancer treatment.
  Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 05/2012; 13(2):296-306. · 2.86 Impact Factor